Dear Doctor Letter (Rote-Hand-Brief) on Cipramil® (citalopram): Risk of dose-dependent QT interval prolongation
2011.10.31
Active substance: citalopram
Important information on the risk of dose-dependent prolongations of the QT interval as well as on altered recommendations as to the maximum dose.
These new scientific findings also apply to all generic marketing authorisations of citalopram. For these generics the BfArM has also initiated implementation of corresponding changes.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN